While DSP (8.0 mg/kg) converted ineffective doses of sctPA (0.5 and 0.25 mg/kg) to effective doses (Figures 2 and 3), it did not improve the outcomes of treatment with scuPA in empyema (Figure 2). The gene discussed is DSP; the disease is empyema.